The earnings call presented a strong growth narrative driven by the Natroba acquisition and Canadian product portfolio, leading to significant revenue and EBITDA growth. However, this was somewhat offset by declines in licensing revenue, particularly from Absorica, and increased expenses. The company's strategic debt repayment and pursuit of growth opportunities provide a balanced outlook.

Company Guidance -

Q2 2025

During the first quarter of 2025, Cipher Pharmaceuticals reported total net revenue of $12 million, marking a 105% increase from the same period in 2024, largely due to the acquisition of the Natroba business. Natroba generated $6.7 million in revenue, achieving gross margins of $5.8 million or approximately 87% when excluding non-cash adjustments. The company's base business yielded $5.3 million in revenue, a 9% decline from the previous year, though Canadian product sales rose by 41%. Total adjusted EBITDA was $6.2 million, up by 73%, with a cash balance of $22 million and a reduced debt of $25 million after a $15 million repayment. The company highlighted its four-fold growth strategy for Natroba, including expansion in the US, a planned launch in Canada, global out-licensing, and acquiring complementary products.

Strong Revenue Growth

Total net revenue increased by 105% to $12 million in Q1 2025 compared to the same period in 2024, largely due to the acquisition of the Natroba business.

Natroba Business Performance

Natroba generated $6.7 million in revenue with a gross margin of approximately 87%, positioning the business well for upcoming warmer months.

Canadian Product Portfolio Growth

Canadian product revenue increased by 41% compared to the same quarter in the prior year, contributing to overall product revenue growth.

Adjusted EBITDA Increase

Adjusted EBITDA rose by 73% to $6.2 million due to the Natroba acquisition and growth in the Canadian product portfolio.

Debt Repayment

A repayment of $15 million was made on the revolving credit facility, reducing the outstanding debt to $25 million.

Cipher Pharmaceuticals (TSE:CPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:CPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	0.21 / -	0.12	―	―	―
May 08, 2025	2025 (Q1)	0.14 / 0.14	0.272	-50.00% (-0.14)	―
Mar 18, 2025	2024 (Q4)	0.26 / 0.18	0.407	-56.67% (-0.23)	―
Nov 07, 2024	2024 (Q3)	0.19 / 0.01	0.367	-96.30% (-0.35)	―
Aug 08, 2024	2024 (Q2)	0.16 / 0.16	0.163	0.00% (0.00)	―
May 09, 2024	2024 (Q1)	0.14 / 0.27	0.136	100.00% (+0.14)	―
Mar 14, 2024	2023 (Q4)	0.13 / 0.41	1.059	-61.54% (-0.65)	―
Nov 09, 2023	2023 (Q3)	0.10 / 0.37	0.136	170.00% (+0.23)	―
Aug 10, 2023	2023 (Q2)	0.12 / 0.16	0.109	50.00% (+0.05)	―
May 11, 2023	2023 (Q1)	0.11 / 0.14	0.109	25.00% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:CPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	C$14.42	C$13.91	-3.54%
Mar 18, 2025	C$11.98	C$13.45	+12.27%
Nov 07, 2024	C$15.54	C$13.88	-10.68%
Aug 08, 2024	C$13.81	C$14.43	+4.49%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cipher Pharmaceuticals Inc (TSE:CPH) report earnings?

Cipher Pharmaceuticals Inc (TSE:CPH) is schdueled to report earning on Aug 07, 2025, Before Open (Confirmed).

What is Cipher Pharmaceuticals Inc (TSE:CPH) earnings time?

Cipher Pharmaceuticals Inc (TSE:CPH) earnings time is at Aug 07, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:CPH EPS forecast?

TSE:CPH EPS forecast for the fiscal quarter 2025 (Q2) is 0.21.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing